24,763$ 38,645Accrued expenses
74,44168,152Total current liabilities
172,120203,044Long-term liabilities: Long-term other liabilities
261,014215,457Commitments and contingenciesEquity:Preferred stock, $0.001 par value; authorized: 5,000,000 shares; no shares issuedand outstanding.
--Common stock, $0.001 par value; authorized: 100,000,000 shares; issued: 72,530,843 and 72,199,837 shares at September 30, 2011 and June 30, 2011, respectively; outstanding: 70,390,825 and 70,059,819 shares at September 30, 2011 and June 30, 2011,
7070Additional paid-in capital
399,905373,963Accumulated other comprehensive income
(170,895)(144,385)Total stockholders' equity
239,021240,327Total liabilities and stockholders' equity
500,035$455,784Non-GAAP Financial MeasuresThis press release includes non-GAAP financial measures, as defined in Regulation G promulgated by the Securities and Exchange Commission, with respect to the three months ended September 30, 2011. "GAAP" refers to generally accepted accounting principles in the United States.
Accuray closed the acquisition of TomoTherapy on June 10, 2011 and TomoTherapy's operations since that date are included in Accuray's consolidated results of operations. Accounting for the impact of this acquisition has resulted in changes to the value of assets and liabilities from the amounts reflected by TomoTherapy prior to the acquisition and the creation of incremental assets and liabilities including intangible assets for developed technol
|SOURCE Accuray Incorporated|
Copyright©2010 PR Newswire.
All rights reserved